RDA Financial Network Sells 1,064 Shares of Edwards Lifesciences Corporation $EW

RDA Financial Network lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 3.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,632 shares of the medical research company’s stock after selling 1,064 shares during the period. RDA Financial Network’s holdings in Edwards Lifesciences were worth $2,630,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Arlington Trust Co LLC lifted its holdings in shares of Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after purchasing an additional 135 shares during the period. Valeo Financial Advisors LLC increased its stake in Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 142 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock worth $123,000 after acquiring an additional 145 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after acquiring an additional 145 shares in the last quarter. Finally, Kera Capital Partners Inc. increased its position in shares of Edwards Lifesciences by 5.0% during the first quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company’s stock worth $224,000 after acquiring an additional 148 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW opened at $77.50 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market cap of $45.50 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The firm’s 50-day simple moving average is $78.92 and its two-hundred day simple moving average is $75.42.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the previous year, the company earned $0.70 earnings per share. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $15,565,087. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,014 shares of company stock valued at $1,698,844. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on EW shares. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, July 25th. William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Barclays increased their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Finally, Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $86.26.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.